Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Total Liabilities (2016 - 2025)

Historic Total Liabilities for Protalix BioTherapeutics (PLX) over the last 17 years, with Q3 2025 value amounting to $29.4 million.

  • Protalix BioTherapeutics' Total Liabilities rose 78.97% to $29.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $29.4 million, marking a year-over-year increase of 78.97%. This contributed to the annual value of $30.2 million for FY2024, which is 4061.54% down from last year.
  • As of Q3 2025, Protalix BioTherapeutics' Total Liabilities stood at $29.4 million, which was up 78.97% from $28.6 million recorded in Q2 2025.
  • In the past 5 years, Protalix BioTherapeutics' Total Liabilities registered a high of $104.4 million during Q2 2021, and its lowest value of $28.6 million during Q2 2025.
  • Moreover, its 5-year median value for Total Liabilities was $63.0 million (2024), whereas its average is $59.0 million.
  • In the last 5 years, Protalix BioTherapeutics' Total Liabilities skyrocketed by 2740.61% in 2024 and then crashed by 5460.06% in 2025.
  • Protalix BioTherapeutics' Total Liabilities (Quarter) stood at $79.7 million in 2021, then fell by 16.65% to $66.4 million in 2022, then dropped by 23.43% to $50.9 million in 2023, then plummeted by 40.62% to $30.2 million in 2024, then fell by 2.81% to $29.4 million in 2025.
  • Its Total Liabilities was $29.4 million in Q3 2025, compared to $28.6 million in Q2 2025 and $28.7 million in Q1 2025.